Clinical Study Of Integrative Medical Therapy On Eldedy Patients With Multiple Myeloma

Objective:Through the comparative study of the clinical effects, the immune function, quality of life and the adverse effect of three treatment programs which are groupl VAD, group2aidi injection+VAD and group3aidi injection+low dose of thalidomide+VAD to explore the clinical value about aidi injection+low-dose thalidomide+VAD in the treatment of elderly multiple myeloma. This research is trying to set up a perfect therapy method for the treatment of elderly patients with MMMethods:The90cases of elderly multiple myeloma patients admitted to our hospital from January2009to December2011are randomly divided into three groups, groupl VAD(n=30), group2aidi injection+VAD(n=30), group3aidi injection+low dose of thalidomide+VAD(n=30).4weeks for a course of treatment, the efficacy, immune function, quality of life KPS score and toxicity were compared after3courses of treatment.Results:(1) The total efficiency of group3is significantly better than that groupl and group2(P<0.05), The total effective of groupl and group2is no significant difference (P>0.05). After treatment, plasma cells in bone marrow, M protein, renal function and (32microglobulin of group3is significantly reduced after treatment (P<0.05) compared with groupl and group2. the hemoglobin of group3increased significantly (P<0.05) compared with groupl and group2.(2) After treatment, the T lymphocyte subsets of CD4+、CD4+/CD8+, NK cells, karnofsky score of group3and group2are significantly increased (P<0.05) compared with groupl.(3) Only constipation and drowsiness of group3is higher than the groupl and the group2, But it can be tolerated by symptomatic treatment, other adverse reaction rate of group3and group2decrease significantly (P<0.05) compared with groupl.Conclusion:Aidi injection can be significantly reduce the chemotherapy adverse reactions, enhance immune function and improved the quality of life in elderly patients with MM, The low-dose thalidomide markedly improves efficacy and has mild adverse effects on senile multiple myeloma, especially for elderly patients with MM. Therefore, the clinical program about Aidi injection+low-dose thalidomide+VAD provides a new idea for the treatment of elderly multiple myeloma, It is worthy of clinical investigation and further application.